4SC AG
Records under this name other than the patents 4SC AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,446,040 | Substituted imidazoquinolines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,908,880 | Substituted imidazoquinolines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,073,913 | Substituted imidazoquinolines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,354,433 | Anti-inflammatory agents as virostatic compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,653,138 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,354,436 | IL17 and Ifn-Gamma Inhibition for the Treatment of Autoimmune Inflammation Formerly held In force · High confidence | In force | High confidence | |
| US 8,592,456 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,785,659 | Novel Method for the Production of Sulphonylpyrroles as Hdac Inhibitors Lapsed on the fee record Ended Jul 22, 2026 · High confidence | Lapsed on the fee record | Ended Jul 22, 2026 | High confidence |
| US 10,005,769 | 2,3-Dihydrobenzofuran-5YL Compounds as Dyrk Kinase Inhibitors Lapsed on the fee record Ended Jun 26, 2026 · High confidence | Lapsed on the fee record | Ended Jun 26, 2026 | High confidence |
| US 9,951,050 | Method of inhibiting DYRK1B Lapsed on the fee record Ended Apr 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | From the USPTO record |